IP Library Granted Patent US 8,268,330
Granted Patent B2
US 8,268,330 · App. 12/532,138 · Granted Sep 18, 2012

Hypoxia inducible factor inducer and methods for using the same

Assignee: Colorado State University Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,330
App. No.
12/532,138
Granted
Sep 18, 2012
Kind
B2
Abstract

The present invention provides vaccine compositions and methods for using the same. Generally, the vaccine is used to prevent infection of a microorganism that produces an HIF inducing compound. Accordingly, vaccines of the invention comprise at least a portion of an HIF inducing compound that is produced by the microorganism.

Claims (11)

1. An immunogenic composition effective to inhibit a mycobacterium infection caused by Mycobacterium tuberculosis or Mycobacterium bovis comprising an isolated siderophore that is produced by said mycobacterium , said siderophore being effective to activate hypoxia inducing factor (HIF) in a sterile aqueous solution or dispersion or as sterile powder for extemporaneous preparation of sterile injectable solutions or dispersions wherein said siderophore is selected from the group consisting of mycobactin, carboxymycobactin, and exochelin.

2. The composition of claim 1 , wherein said mycobacterium is Mycobacterium tuberculosis and said siderophore is naturally occurring.

3. The composition of claim 1 , wherein said siderophore is recognized by the immune system of said subject.

4. The composition of claim 1 , wherein said siderophore is mycobactin.

5. The composition of claim 1 wherein said mycobacterium is Mycobacterium tuberculosis and said composition further comprises an attenuated or inactivated Mycobacterium tuberculosis.

6. The composition of claim 3 wherein said mycobacterium is Mycobacterium tuberculosis , said siderophore is mycobactin and said composition further comprises an attenuated or inactivated Mycobacterium tuberculosis.

7. An immunogenic composition for inhibition of Mycobacterium tuberculosis infection for administration to a subject in need thereof, said composition comprising isolated, naturally occurring mycobactin, carboxymycobactin or exochelin produced by said M. tuberculosis , in a sterile aqueous solution or dispersion or as sterile powder for extemporaneous preparation of sterile injectable solutions or dispersions, said mycobactin, carboxymycobactin or exochelin being recognized by the immune system of said subject.

8. The composition of claim 7 wherein said mycobacterium is Mycobacterium tuberculosis , said siderophore is mycobactin and said composition further comprises an attenuated or inactivated Mycobacterium tuberculosis.

9. A method for stimulating an immune response against Mycobacterium tuberculosis in a subject comprising administering the composition of claim 1 .

10. The method of claim 9 , wherein the composition further comprises an epitope of Mycobacterium tuberculosis.

11. The method of claim 9 , wherein the composition further comprises an attenuated or inactivated Mycobacterium tuberculosis .

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 17, 2021
From: COLORADO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 058167/0406 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2010
From: BASARABA, RANDALL JOSEPH; BIELEFELDT-OHMANN, HELLE
To: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 025516/0893 →
CONFIRMATORY LICENSE Recorded Sep 30, 2009
From: COLORADO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 023302/0174 →
Continuity (2)
Provisional Application 60919058 · Mar 19, 2007
Related Publication 20100112004A1 · May 6, 2010